Literature DB >> 19861346

The role of the central renin-angiotensin system in Parkinson's disease.

Birgit Mertens1, Patrick Vanderheyden, Yvette Michotte, Sophie Sarre.   

Abstract

Since the discovery of a renin-angiotensin system (RAS) in the brain, several studies have linked this central RAS to neurological disorders such as ischaemia, Alzheimer's disease and depression. In the last decade, evidence has accumulated that the central RAS might also play a role in Parkinson's disease. Although the exact cause of this progressive neurodegenerative disorder of the basal ganglia remains unidentified, inflammation and oxidative stress have been suggested to be key factors in the pathogenesis and the progression of the disease. Since angiotensin II is a pro-inflammatory compound that can induce the production of reactive oxygen species due to activation of the NADPH-dependent oxidase complex, this peptide might contribute to dopaminergic cell death. In this review, three different strategies to interfere with the pathogenesis or the progression of Parkinson's disease are discussed. They include inhibition of the angiotensin-converting enzyme, blockade of the angiotensin II type 1 receptor and stimulation of the angiotensin II type 2 receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861346     DOI: 10.1177/1470320309347789

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  36 in total

Review 1.  Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2011-09-22       Impact factor: 5.046

Review 2.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 3.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

Authors:  Juan M Saavedra; Enrique Sánchez-Lemus; Julius Benicky
Journal:  Psychoneuroendocrinology       Date:  2010-10-29       Impact factor: 4.905

4.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

Review 5.  New insights on NOX enzymes in the central nervous system.

Authors:  Zeynab Nayernia; Vincent Jaquet; Karl-Heinz Krause
Journal:  Antioxid Redox Signal       Date:  2014-01-16       Impact factor: 8.401

Review 6.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

7.  The novel nonapeptide acein targets angiotensin converting enzyme in the brain and induces dopamine release.

Authors:  Jérémie Neasta; Charlène Valmalle; Anne-Claire Coyne; Eric Carnazzi; Gilles Subra; Jean-Claude Galleyrand; Didier Gagne; Céline M'Kadmi; Nicole Bernad; Gilbert Bergé; Sonia Cantel; Philippe Marin; Jacky Marie; Jean-Louis Banères; Marie-Lou Kemel; Valérie Daugé; Karine Puget; Jean Martinez
Journal:  Br J Pharmacol       Date:  2016-03-08       Impact factor: 8.739

8.  The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative.

Authors:  L D Carbone; S Vasan; R L Prentice; G Harshfield; B Haring; J A Cauley; K C Johnson
Journal:  Osteoporos Int       Date:  2019-06-17       Impact factor: 4.507

Review 9.  Immunological regulation of neurogenic niches in the adult brain.

Authors:  O Gonzalez-Perez; F Gutierrez-Fernandez; V Lopez-Virgen; J Collas-Aguilar; A Quinones-Hinojosa; J M Garcia-Verdugo
Journal:  Neuroscience       Date:  2012-09-15       Impact factor: 3.590

10.  Perindopril may improve the hippocampal reduced glutathione content in rats.

Authors:  Tahereh Mashhoody; Karim Rastegar; Fatemeh Zal
Journal:  Adv Pharm Bull       Date:  2013-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.